Precision Biosciences Inc. (DTIL)
Strength Seen in Precision BioSciences (DTIL): Can Its 12.3% Jump Turn into More Strength?
Precision BioSciences (DTIL) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Precision BioSciences (DTIL) Reports Q1 Loss, Tops Revenue Estimates
Precision BioSciences (DTIL) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to a loss of $2.21 per share a year ago.
Precision BioSciences, Inc. (DTIL) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript
Precision BioSciences, Inc. (DTIL) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript
Should You Buy Precision BioSciences (DTIL) After Golden Cross?
Precision BioSciences, Inc. (DTIL) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, DTIL's 50-day simple moving average broke out above its 200-day moving average; this is known as a "golden cross.
Precision BioSciences, Inc. (DTIL) Shareholder/Analyst Call Transcript
Precision BioSciences, Inc. (DTIL) Shareholder/Analyst Call Transcript
Precision BioSciences (DTIL) Surpasses Q4 Earnings and Revenue Estimates
Precision BioSciences (DTIL) came out with quarterly earnings of $0.36 per share, beating the Zacks Consensus Estimate of a loss of $0.21 per share. This compares to a loss of $3.2 per share a year ago.
Precision BioSciences: Potential Proof-Of-Concept Data For HBV Cure In 2026
Precision BioSciences offers high-risk, high-reward potential, trading below cash with key HBV and DMD data catalysts expected in 2026. PBGENE-HBV targets both cccDNA and integrated HBV DNA, aiming for a functional HBV cure superior to downstream competitors. Recent $75M capital raise extends DTIL's cash runway through major readouts, supporting continued clinical development and operational flexibility.
Precision Biosciences: Still Swinging And Finally Drawing Blood
Precision BioSciences is advancing a de-risked gene-editing pipeline with promising clinical data and multi-year cash runway. PBGENE-HBV shows compelling early efficacy and safety, positioning DTIL for a potential breakthrough in functional cures for chronic hepatitis B. DTIL maintains a 2/5 conviction rating due to technical weakness, competitive risks, and the need for cleaner bullish signals before adding to positions.
Precision BioSciences, Inc. (DTIL) Discusses ARCUS Platform Progress and ELIMINATE-B Clinical Trial Update for Chronic Hepatitis B Transcript
Precision BioSciences, Inc. ( DTIL ) Discusses ARCUS Platform Progress and ELIMINATE-B Clinical Trial Update for Chronic Hepatitis B November 11, 2025 8:00 AM EST Company Participants Naresh Tanna - Chief of Staff to CEO & Head of Investor Relations Michael Amoroso - President, CEO & Director Mark Sulkowski Cassie Gorsuch - Chief Scientific Officer John Kelly - CFO & Principal Accounting Officer Conference Call Participants Soumit Roy - JonesTrading Institutional Services, LLC, Research Division Farzin Haque - Jefferies LLC, Research Division Patrick Trucchio - H.C. Wainwright & Co, LLC, Research Division Ry Forseth - Guggenheim Securities, LLC, Research Division Presentation Operator Thank you for standing by.
Precision BioSciences (DTIL) Moves 11.1% Higher: Will This Strength Last?
Precision BioSciences (DTIL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Precision BioSciences (DTIL) Reports Q2 Loss, Lags Revenue Estimates
Precision BioSciences (DTIL) came out with a quarterly loss of $2.13 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to earnings of $3.46 per share a year ago.
Precision BioSciences (DTIL) Reports Q1 Loss, Lags Revenue Estimates
Precision BioSciences (DTIL) came out with a quarterly loss of $2.21 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to loss of $0.35 per share a year ago.
